Indications for Heparin Sodium:
Adults and Children:
See full labeling. Individualize based on lab results and disease.
Heparin Sodium Contraindications:
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT). History of thrombocytopenia with pentosan polysulfate. Hypersensitivity to pork products. When blood coagulation testing is not feasible. Uncontrolled bleeding state, except when due to disseminated intravascular coagulation.
Heparin Sodium Warnings/Precautions:
IM use not recommended. Confirm choice of correct strength prior to administration. Monitor for any degree of thrombocytopenia; discontinue if platelet count falls <100000/mm3 or if recurrent thrombosis develops; evaluate for HIT and HITT; if needed, give alternative anticoagulant. Major bleeding or conditions with increased risk of hemorrhage (eg, bacterial endocarditis, severe hypertension, surgery, hemophilia, hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy, ulcerative lesions, continuous GI tube drainage, menstruation, liver disease with impaired hemostasis). Monitor blood coagulation tests (discontinue if test is unduly prolonged or if hemorrhage occurs), platelets, hematocrit, and occult blood in stool during therapy, regardless of the route of administration. Heparin resistance (monitor). History of allergy. Not interchangeable (unit-for-unit) with low molecular weight heparins. Women >60yrs of age. Elderly. Neonates/infants (gasping syndrome due to benzyl alcohol), pregnancy, nursing mothers: use preservative-free formulations.
Heparin Sodium Classification:
Heparin Sodium Interactions:
Potentiated by anticoagulants (eg, dicumerol, warfarin), antiplatelets (eg, salicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, celecoxib, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists including abciximab, eptifibatide, tirofiban) and others; caution. Antagonized by digitalis, tetracyclines, nicotine, antihistamines, IV nitroglycerin. Potentiated by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency; reduce heparin dose.
Hemorrhage, thrombocytopenia, HIT and HITT, inj site irritation, hypersensitivity reactions, increased aminotransferase levels.
Formerly known under the brand names Panheparin, Lipo-Hepin, Liquaemin.